Altimmune, Inc. (NASDAQ:ALT - Get Free Report) saw unusually large options trading on Tuesday. Traders bought 18,846 call options on the company. This represents an increase of 185% compared to the average volume of 6,618 call options.
Insiders Place Their Bets
In other Altimmune news, Director David Drutz sold 16,011 shares of the business's stock in a transaction on Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the sale, the director now directly owns 41,958 shares in the company, valued at approximately $289,510.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.10% of the stock is owned by company insiders.
Hedge Funds Weigh In On Altimmune
Institutional investors and hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP raised its position in shares of Altimmune by 142.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company's stock valued at $3,791,000 after purchasing an additional 335,444 shares in the last quarter. Knoll Capital Management LLC boosted its stake in Altimmune by 183.6% during the first quarter. Knoll Capital Management LLC now owns 567,219 shares of the company's stock valued at $5,774,000 after buying an additional 367,219 shares in the last quarter. Farallon Capital Management LLC lifted its holdings in shares of Altimmune by 1,282.4% during the first quarter. Farallon Capital Management LLC now owns 470,000 shares of the company's stock valued at $4,785,000 after purchasing an additional 436,000 shares during the last quarter. BBR Partners LLC lifted its holdings in shares of Altimmune by 4.5% during the second quarter. BBR Partners LLC now owns 374,784 shares of the company's stock valued at $2,492,000 after purchasing an additional 16,271 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of Altimmune by 542.8% during the second quarter. SG Americas Securities LLC now owns 254,571 shares of the company's stock valued at $1,693,000 after purchasing an additional 214,968 shares during the last quarter. Hedge funds and other institutional investors own 78.05% of the company's stock.
Altimmune Price Performance
NASDAQ ALT traded up $2.14 on Tuesday, reaching $9.49. The company had a trading volume of 18,531,391 shares, compared to its average volume of 3,829,654. The firm has a market capitalization of $674.45 million, a PE ratio of -5.51 and a beta of 0.09. Altimmune has a 1 year low of $2.32 and a 1 year high of $14.84. The firm has a 50-day moving average of $6.83 and a 200-day moving average of $6.85.
Wall Street Analysts Forecast Growth
ALT has been the topic of several recent research reports. Evercore ISI upgraded Altimmune to a "strong-buy" rating in a research report on Friday, August 9th. B. Riley reiterated a "buy" rating and set a $20.00 target price on shares of Altimmune in a research report on Monday, August 12th. UBS Group assumed coverage on Altimmune in a research report on Tuesday. They set a "buy" rating and a $26.00 target price on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $12.00 target price on shares of Altimmune in a research report on Thursday, August 22nd. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $20.00.
Check Out Our Latest Report on Altimmune
About Altimmune
(
Get Free Report)
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
Featured Articles
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
